# A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

> **NCT06794541** · PHASE2 · RECRUITING · sponsor: **Tetraphase Pharmaceuticals, Inc** · enrollment: 35 (estimated)

## Conditions studied

- Complicated Intra-abdominal Infections (cIAI)

## Interventions

- **DRUG:** IV Eravacycline 2mg/kg
- **DRUG:** IV Eravacycline 1.5mg/kg

## Key facts

- **NCT ID:** NCT06794541
- **Lead sponsor:** Tetraphase Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2029-02-17
- **Final completion:** 2029-03-19
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06794541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06794541, "A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06794541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*